Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Relationship between cardiorespiratory phase coherence during hypoxia and genetic polymorphism in humans.

Lancaster G, Debevec T, Millet GP, Poussel M, Willis SJ, Mramor M, Goričar K, Osredkar D, Dolžan V, Stefanovska A.

J Physiol. 2020 Jan 20. doi: 10.1113/JP278829. [Epub ahead of print]

PMID:
31957891
2.

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort.

Jensterle M, Kravos NA, Ferjan S, Goricar K, Dolzan V, Janez A.

Endocr Connect. 2020 Jan;9(1):44-54. doi: 10.1530/EC-19-0449.

3.

Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment.

Hrovatin K, Kunej T, Dolžan V.

Am J Med Genet B Neuropsychiatr Genet. 2020 Mar;183(2):113-127. doi: 10.1002/ajmg.b.32766. Epub 2019 Oct 31. Review.

PMID:
31674148
4.

Detection of metabolic syndrome burden in healthy young adults may enable timely introduction of disease prevention.

Šoštarič A, Jenko B, Kozjek NR, Ovijač D, Šuput D, Milisav I, Dolžan V.

Arch Med Sci. 2019 Sep;15(5):1184-1194. doi: 10.5114/aoms.2019.87462. Epub 2019 Aug 23.

5.

Association of NLRP3 and CARD8 Inflammasome Polymorphisms With Aseptic Loosening After Primary Total Hip Arthroplasty.

Mavčič B, Antolič V, Dolžan V.

J Orthop Res. 2020 Feb;38(2):417-421. doi: 10.1002/jor.24474. Epub 2019 Sep 26.

PMID:
31529732
6.

DEPTOR polymorphisms influence late complications in Type 2 diabetes patients.

Klen J, Goričar K, Horvat S, Stojan J, Dolžan V.

Pharmacogenomics. 2019 Aug;20(12):879-890. doi: 10.2217/pgs-2019-0058.

PMID:
31453770
7.

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity.

Ferjan S, Jensterle M, Oblak T, Zitnik IP, Marc J, Goricar K, Dolzan V, Janez A.

J Int Med Res. 2019 Oct;47(10):4691-4700. doi: 10.1177/0300060519865351. Epub 2019 Aug 23. No abstract available.

8.

Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts.

Just KS, Turner RM, Dolžan V, Cecchin E, Swen JJ, Gurwitz D, Stingl JC.

Clin Pharmacol Ther. 2019 Aug;106(2):313-316. doi: 10.1002/cpt.1471. Epub 2019 Jun 25. No abstract available.

9.

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.

Štrbac D, Goričar K, Dolžan V, Kovač V.

Dis Markers. 2019 May 2;2019:1242964. doi: 10.1155/2019/1242964. eCollection 2019.

10.

Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson's Disease.

Redenšek S, Jenko Bizjan B, Trošt M, Dolžan V.

Front Genet. 2019 May 16;10:461. doi: 10.3389/fgene.2019.00461. eCollection 2019.

11.

ADORA2A Polymorphisms Influence Methotrexate Adverse Events in Rheumatoid Arthritis.

Kobold N, Jenko B, Tomšič M, Dolžan V, Praprotnik S.

Isr Med Assoc J. 2019 May;5(21):333-338.

12.

Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children.

Smigoc Schweiger D, Goricar K, Hovnik T, Mendez A, Bratina N, Brecelj J, Vidan-Jeras B, Battelino T, Dolzan V.

Front Pediatr. 2019 Mar 12;7:63. doi: 10.3389/fped.2019.00063. eCollection 2019.

13.

The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma.

Levpuscek K, Goricar K, Kovac V, Dolzan V, Franko A.

Radiol Oncol. 2019 Mar 14;53(2):206-212. doi: 10.2478/raon-2019-0016.

14.

Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.

Senk B, Goricar K, Kovac V, Dolzan V, Franko A.

Radiol Oncol. 2019 Mar 3;53(1):96-104. doi: 10.2478/raon-2019-0009.

15.

Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.

Redenšek S, Flisar D, Kojović M, Kramberger MG, Georgiev D, Pirtošek Z, Trošt M, Dolžan V.

J Neuroinflammation. 2019 Feb 27;16(1):50. doi: 10.1186/s12974-019-1439-y.

16.

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease.

Redenšek S, Flisar D, Kojović M, Gregorič Kramberger M, Georgiev D, Pirtošek Z, Trošt M, Dolžan V.

Front Pharmacol. 2019 Jan 28;10:8. doi: 10.3389/fphar.2019.00008. eCollection 2019.

17.

Variants in the 14q32 miRNA cluster are associated with osteosarcoma risk in the Spanish population.

Martin-Guerrero I, Bilbao-Aldaiturriaga N, Gutierrez-Camino A, Santos-Zorrozua B, Dolžan V, Patiño-Garcia A, Garcia-Orad A.

Sci Rep. 2018 Oct 18;8(1):15414. doi: 10.1038/s41598-018-33712-4.

18.

Pharmacogenomic markers of glucocorticoid response in the initial phase of remission induction therapy in childhood acute lymphoblastic leukemia.

Gasic V, Zukic B, Stankovic B, Janic D, Dokmanovic L, Lazic J, Krstovski N, Dolzan V, Jazbec J, Pavlovic S, Kotur N.

Radiol Oncol. 2018 Sep 11;52(3):296-306. doi: 10.2478/raon-2018-0034.

19.

SLC6A4 5HTTLPR Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome.

Šenk B, Goričar K, Kravos NA, Jensterle Sever M, Janež A, Dolžan V.

Int J Endocrinol. 2018 Jul 17;2018:6130487. doi: 10.1155/2018/6130487. eCollection 2018.

20.

Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma.

Strbac D, Goricar K, Dolzan V, Kovac V.

Radiol Oncol. 2018 Feb 7;52(2):160-166. doi: 10.2478/raon-2018-0005. eCollection 2018 Jun.

21.

Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk.

Gutierrez-Camino A, Martin-Guerrero I, Dolzan V, Jazbec J, Carbone-Bañeres A, Garcia de Andoin N, Sastre A, Astigarraga I, Navajas A, Garcia-Orad A.

Oncotarget. 2018 May 1;9(33):22907-22914. doi: 10.18632/oncotarget.25144. eCollection 2018 May 1.

22.

Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.

López-Rodríguez R, Ferreiro-Iglesias A, Lima A, Bernardes M, Pawlik A, Paradowska-Gorycka A, Świerkot J, Slezak R, Dolžan V, González-Álvaro I, Narváez J, Cáliz R, Pérez-Pampín E, Mera-Varela A, Vidal-Bralo L, Acuña Ochoa JG, Conde C, Gómez-Reino JJ, González A.

Sci Rep. 2018 May 9;8(1):7342. doi: 10.1038/s41598-018-25634-y.

23.

The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma.

Franko A, Kotnik N, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V.

Radiol Oncol. 2018 Jan 24;52(1):105-111. doi: 10.2478/raon-2018-0004. eCollection 2018 Mar.

24.
25.

Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA.

Ferdin J, Goričar K, Dolžan V, Plemenitaš A, Martin JN, Peterlin BM, Deeks SG, Lenassi M.

PLoS One. 2018 Jan 24;13(1):e0191613. doi: 10.1371/journal.pone.0191613. eCollection 2018.

26.

From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms.

Redenšek S, Dolžan V, Kunej T.

OMICS. 2018 Jan;22(1):1-16. doi: 10.1089/omi.2017.0181.

27.

Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach.

Kotnik BF, Jazbec J, Grabar PB, Rodriguez-Antona C, Dolzan V.

Radiol Oncol. 2017 Sep 18;51(4):455-462. doi: 10.1515/raon-2017-0040. eCollection 2017 Dec.

28.

Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.

Štrbac D, Goričar K, Dolžan V, Kovač V.

Dis Markers. 2017;2017:8069529. doi: 10.1155/2017/8069529. Epub 2017 Sep 12.

29.

The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy.

Bertok S, Dolžan V, Goričar K, Podkrajšek KT, Battelino T, Rener-Primec Z.

Seizure. 2017 Oct;51:9-13. doi: 10.1016/j.seizure.2017.07.007. Epub 2017 Jul 20.

30.

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Jul;102(1):152. doi: 10.1002/cpt.725. No abstract available.

PMID:
30239993
31.

The role of single nucleotide polymorphisms of CYP3A and ABCB1 on tacrolimus predose concentration in kidney transplant recipients.

Mlinšek G, Dolžan V, Goričar K, Buturović-Ponikvar J, Arnol M.

Clin Nephrol. 2017 Supplement 1;88(13):115-118. doi: 10.5414/CNP88FX25.

PMID:
28655393
32.

Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis.

Zajc Avramovič M, Dolžan V, Toplak N, Accetto M, Lusa L, Avčin T.

J Rheumatol. 2017 Aug;44(8):1216-1223. doi: 10.3899/jrheum.160950. Epub 2017 Jun 1.

PMID:
28572465
33.

Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.

Goričar K, Kovač V, Dolžan V.

Sci Rep. 2017 Apr 19;7:46537. doi: 10.1038/srep46537.

34.

NLRP3 and CARD8 Polymorphisms Influence Higher Disease Activity in Rheumatoid Arthritis.

Jenko B, Praprotnik S, Tomšic M, Dolžan V.

J Med Biochem. 2016 Sep;35(3):319-323. doi: 10.1515/jomb-2016-0008. Epub 2016 Jul 6.

35.

Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?

Redenšek S, Trošt M, Dolžan V.

Front Aging Neurosci. 2017 Feb 10;9:20. doi: 10.3389/fnagi.2017.00020. eCollection 2017. Review.

36.

Antioxidant polymorphisms do not influence the risk of epilepsy or its drug resistance after neonatal hypoxic-ischemic brain injury.

Esih K, Goričar K, Dolžan V, Rener-Primec Z.

Seizure. 2017 Mar;46:38-42. doi: 10.1016/j.seizure.2017.01.005. Epub 2017 Feb 3.

37.

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017.

38.

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602. Erratum in: Clin Pharmacol Ther. 2017 Jul;102(1):152.

PMID:
28027596
39.

Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinoma.

Krhin B, Goricar K, Gazic B, Dolzan V, Besic N.

Radiol Oncol. 2016 Jul 19;50(3):289-96. doi: 10.1515/raon-2016-0031. eCollection 2016 Sep 1.

40.

Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy.

Vozikis A, Cooper DN, Mitropoulou C, Kambouris ME, Brand A, Dolzan V, Fortina P, Innocenti F, Lee MT, Leyens L, Macek M Jr, Al-Mulla F, Prainsack B, Squassina A, Taruscio D, van Schaik RH, Vayena E, Williams MS, Patrinos GP.

Public Health Genomics. 2016;19(6):352-363. doi: 10.1159/000449152. Epub 2016 Sep 28. Review.

41.

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172595.

42.

Minimum information required for a DMET experiment reporting.

Kumuthini J, Mbiyavanga M, Chimusa ER, Pathak J, Somervuo P, Van Schaik RH, Dolzan V, Mizzi C, Kalideen K, Ramesar RS, Macek M, Patrinos GP, Squassina A.

Pharmacogenomics. 2016 Sep;17(14):1533-45. doi: 10.2217/pgs-2016-0015. Epub 2016 Aug 22.

43.

Expression of miRNA and Occurrence of Distant Metastases in Patients with Hürthle Cell Carcinoma.

Petric R, Gazic B, Goricar K, Dolzan V, Dzodic R, Besic N.

Int J Endocrinol. 2016;2016:8945247. doi: 10.1155/2016/8945247. Epub 2016 Jul 28.

44.

A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility.

Bilbao-Aldaiturriaga N, Askaiturrieta Z, Granado-Tajada I, Goričar K, Dolžan V, For The Slovenian Osteosarcoma Study Group, Garcia-Miguel P, Garcia de Andoin N, Martin-Guerrero I, Garcia-Orad A.

Pediatr Res. 2016 Oct;80(4):472-9. doi: 10.1038/pr.2016.120. Epub 2016 Jun 3. Review.

PMID:
27438225
45.

The association between antioxidant enzyme polymorphisms and cerebral palsy after perinatal hypoxic-ischaemic encephalopathy.

Esih K, Goričar K, Dolžan V, Rener-Primec Z.

Eur J Paediatr Neurol. 2016 Sep;20(5):704-8. doi: 10.1016/j.ejpn.2016.05.018. Epub 2016 Jun 2.

PMID:
27302388
46.

Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia.

Terzić T, Kastelic M, Dolžan V, Plesničar BK.

Psychiatr Danub. 2016 Jun;28(2):127-31.

47.

Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.

Jenko B, Lusa L, Tomsic M, Praprotnik S, Dolzan V.

Pharmacogenomics J. 2017 Oct;17(5):412-418. doi: 10.1038/tpj.2016.36. Epub 2016 May 24.

PMID:
27217051
48.

Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia.

Turčin A, Dolžan V, Porcelli S, Serretti A, Plesničar BK.

OMICS. 2016 May;20(5):283-9. doi: 10.1089/omi.2016.0003.

PMID:
27195966
49.

Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Milosheska D, Lorber B, Vovk T, Kastelic M, Dolžan V, Grabnar I.

Br J Clin Pharmacol. 2016 Aug;82(2):399-411. doi: 10.1111/bcp.12984. Epub 2016 May 29.

50.

Antioxidant defence-related genetic variants are not associated with higher risk of secondary thyroid cancer after treatment of malignancy in childhood or adolescence.

Vodusek AL, Goricar K, Gazic B, Dolzan V, Jazbec J.

Radiol Oncol. 2016 Feb 16;50(1):80-6. doi: 10.1515/raon-2015-0026. eCollection 2016 Mar 1.

Supplemental Content

Loading ...
Support Center